Content available at: https://www.ipinnovative.com/open-access-journals

IP International Journal of Ocular Oncology and Oculoplasty

Journal homepage: https://www.ijooo.org/

Editorial

Thyroid eye disease and orbital decompression: The precision art of reclaiming balance

Ankit S. Varshney[1]*

[1]Dept. of Optometry, Shree Bharatimaiya College of Optometry & Physiotherapy, Surat, Gujarat, India

Received: 17-04-2025; **Accepted:** 06-05-2025; **Available Online**: 31-05-2025

1. Introduction

Thyroid Eye Disease (TED), or thyroid-associated orbitopathy, presents a formidable clinical challenge, intricately weaving autoimmune inflammation with profound functional compromise and life-altering disfigurement.[1,2] For patients, TED transcends a mere ocular diagnosis—it is a relentless disruption of identity, vision, and psychosocial well-being, often dictating how they interact with the world and perceive themselves.[3] Among the therapeutic arsenal, orbital decompression emerges as a pivotal yet exquisitely delicate intervention, demanding the pinnacle of technical mastery and discerning clinical judgment from oculoplastic surgeons and orbital specialists.

As Thomas Merton wisely said, "Happiness is not a matter of intensity but of balance and order and rhythm and harmony." In TED, balance isn't just a philosophical aspiration—it is the very blueprint of surgical success. Each millimeter of decompression represents a meticulously calibrated decision, aiming to optimize proptosis reduction while diligently mitigating risks such as new-onset diplopia, aesthetic asymmetry, and long-term orbital instability. This act of restoration is not merely about removing bone or repositioning tissue—it is about restoring function, identity, and hope.[1,4]

1.1. Understanding the disease: Timing, risk factors, and classification

TED is a rare but significant autoimmune orbital inflammatory condition. Globally, its annual incidence is approximately 16 cases per 100,000 women and 2.9 per 100,000 men, while among Graves' disease patients, prevalence ranges from 25% to 50%.[1,5,6] In India, reported TED prevalence among thyroid dysfunction patients varies from 28% to over 47%. Indian data also suggests a less pronounced female-to-male ratio and potentially milder proptosis but a higher risk of optic neuropathy at presentation—perhaps due to unique anatomical predispositions or delayed diagnosis.[6,7] These trends highlight TED's considerable public health burden and underscore the need for region-specific understanding.

Multiple risk factors modulate TED's onset and severity. While TED commonly affects middle-aged women, men often present with more severe, vision-threatening disease. Smoking remains the most significant modifiable risk factor, dramatically increasing both incidence and clinical severity. Other contributors include age (with bimodal peaks in the 40s and 60s), genetic predisposition, and the thyroid status—predominantly hyperthyroid but also euthyroid and hypothyroid states. Certain medical interventions like Radioactive Iodine Therapy (RAIT) can exacerbate TED if not properly managed.[8,9]

*Corresponding author: Ankit S. Varshney
Email: ankitsvarshnet@yahoo.com

http://doi.org/10.18231/j.ijooo.2025.001

Clinicians evaluate TED severity using classification systems such as NOSPECS: No signs/symptoms, Only signs (e.g., lid retraction), Soft tissue involvement, Proptosis, Extraocular muscle involvement, Corneal involvement, and Sight loss. TED typically progresses from an active inflammatory phase—marked by pain, redness, and swelling—to an inactive fibrotic phase, where inflammation subsides but structural changes persist. Orbital decompression is most effective during the inactive phase, though in urgent cases such as compressive optic neuropathy or exposure keratopathy, surgery may be necessary regardless of disease activity.[1,10]

Early diagnosis, optimal control of thyroid function, and interdisciplinary collaboration are crucial to preventing vision loss and disfigurement. This evolving understanding has ushered in a new era of medical therapy. Biological agents like teprotumumab (an IGF-1R inhibitor) have shown promise in reducing inflammation and proptosis during active TED. These therapies are invaluable adjuncts, often serving as bridges to surgical precision, reinforcing the need for a dynamic, multi-modal treatment approach.[11]

1.2. Surgical philosophy: Precision with prudence

The surgical options for TED include medial wall, lateral wall, and orbital floor decompressions, as well as targeted fat removal. Each technique offers different degrees of orbital volume expansion and addresses specific anatomical needs. Medial wall decompression is highly effective for optic nerve relief, while lateral wall and floor approaches contribute significantly to proptosis reduction. The choice of technique must be tailored, guided by proptosis severity, presence of optic neuropathy, ocular motility status, and unique orbital anatomy.[12]

The surgical process is analogous to bespoke tailoring: overcorrection may result in enophthalmos or disabling diplopia, while undercorrection leaves patients with persistent cosmetic and functional concerns. Innovations such as endoscopic decompression, image-guided navigation, and customized implants have significantly enhanced surgical precision. Endoscopic techniques allow for targeted bone removal through minimal incisions. Navigation systems provide real-time feedback, while customized implants facilitate accurate orbital reconstruction. These advances improve patient outcomes, reduce recovery times, and minimize complications.[13]

Looking ahead, artificial intelligence (AI) may further enhance care—enabling earlier diagnosis via imaging analytics, predicting disease progression, and even aiding in personalized surgical planning with robot-assisted precision.[14]

1.3. Clinical judgment and multidisciplinary collaboration

Optimal outcomes hinge on careful patient selection and multidisciplinary collaboration. A coordinated team—comprising endocrinologists, ophthalmologists, strabismus specialists, and oculoplastic surgeons—is essential for holistic care. The European Group on Graves' Orbitopathy (EUGOGO) guidelines emphasize surgical decompression as a cornerstone treatment for disfiguring proptosis, optic neuropathy, or exposure keratopathy in the inactive phase, integrated into a stepwise therapeutic plan.[15]

The American Academy of Ophthalmology (AAO) also advocates for comprehensive, activity-based management within a multidisciplinary framework. The Asia-Pacific consensus (APAO–APSPOS) further highlights the need for customized decompression strategies accounting for anatomical and healthcare disparities in the region.[16,17]

The American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) recommends a staged surgical approach: decompression, followed by strabismus correction, and then eyelid surgery. This sequence maximizes both aesthetic harmony and functional restoration.[18,19]

Importantly, clinical decisions must center around the patient—not merely imaging findings. As the clinical maxim reminds us, "Treat the patient, not just the scan." Symptoms, disease activity, and personal goals must shape the therapeutic strategy.

1.4. The human perspective: beyond anatomy[4,20]

TED profoundly alters how patients see the world—and how the world sees them. Facial disfigurement can lead to social withdrawal, anxiety, and depression. Orbital decompression, therefore, is not simply a cosmetic procedure—it is restorative, improving psychosocial well-being, rekindling social engagement, and restoring self-confidence.

As artist Thomas Kinkade said, "Balance, peace, and joy are the fruit of a successful life." For oculoplastic surgeons, these "fruits" stem from not only technical expertise but also deep empathy, attentive listening, and holistic patient-centered care. Our role extends beyond the operating room, profoundly influencing patients' lives.

1.5. Conclusion: The art of restoring wholeness

Orbital decompression in TED is more than surgical execution—it is the pursuit of balance. It represents the delicate harmony between anatomical correction and patient experience, between necessary intervention and respectful restraint. With evolving evidence, technological innovation, and integrated care models, clinicians are better equipped than ever to guide TED patients toward restored vision, confidence, and dignity.

Ongoing collaborative research, innovation in therapy, and robust patient advocacy will ensure no TED patient feels alone or hopeless. Ultimately, the highest ideals of medicine are realized not just in restored function, but in restored wholeness.

And as in TED—as in life—the greatest mastery lies in knowing when to act, and exactly how much to do. Because, in this precision art, balance is everything.

2. Conflict of Interest

There are no conflicts of interest

References

1. Shah SS, Patel BC. Thyroid Eye Disease [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan– [updated 2023 May 22; cited 2025 May 29]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582134/
2. Maheshwari R, Weis E. Thyroid associated orbitopathy. *Indian J Ophthalmol*. 2012;60(2):87–93.
3. Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. *Curr Opin Ophthalmol*. 2011;22(5):385–90.
4. Braun TL, Bhadkamkar MA, Jubbal KT, Weber AC, Marx DP. Orbital decompression for thyroid eye disease. *Semin Plast Surg*. 2017;31(1):40–5.
5. McAlinden C. An overview of thyroid eye disease. *Eye Vis (Lond)*. 2014;1:9.
6. Yu CY, Ford RL, Wester ST, Shriver EM. Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. *Indian J Ophthalmol*. 2022;70(7):2335–45.
7. Mathur C, Singh S, Sharma S. Prevalence and risk factors of thyroid-associated ophthalmopathy among Indians. *Int J Adv Med*. 2016;3(3):662–5.
8. Rashad R, Pinto R, Li E, Sohrab M, Distefano AG. Thyroid eye disease. *Life (Basel)*. 2022;12(12):2084.
9. Muralidhar A, Das S, Tiple S. Clinical profile of thyroid eye disease and factors predictive of disease severity. *Indian J Ophthalmol*. 2020;68(8):1629–34.
10. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves' ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. *J Ophthalmol*. 2015;2015:249125.
11. Men C, Kossler A, Wester ST. Updates on the understanding and management of thyroid eye disease. *Ther Adv Ophthalmol*. 2021;13:251584142110277.
12. Jefferis JM, Jones RK, Currie ZI, Tan JH, Salvi SM. Orbital decompression for thyroid eye disease: methods, outcomes, and complications. *Eye (Lond)*. 2018;32(3):626–36.
13. Cheng AMS, Wei YH, Liao SL. Strategies in surgical decompression for thyroid eye disease. *Oxid Med Cell Longev.* 2020;2020:3537675.
14. Williams J, Sahu P. Surgical management of the orbit in thyroid eye disease: lateral orbital decompression. *Curr Opin Otolaryngol Head Neck Surg*. 2021;29(4):289–93.
15. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. *Eur J Endocrinol*. 2021;185(4):G43–G67.
16. Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. *Thyroid*. 2022;32(12):1439–70.
17. Reich SS, Null RC, Timoney PJ, Sokol JA. Trends in orbital decompression techniques of surveyed American Society of Ophthalmic Plastic and Reconstructive Surgery members. *Ophthalmic Plast Reconstr Surg*. 2016;32(6):434–7.
18. Rashad R, Pinto R, Li E, Sohrab M, Distefano AG. Thyroid eye disease. *Life (Basel).* 2022;12(12):2084.
19. Douglas RS, Kossler AL, Abrams J, Briceño CA, Gay D, Harrison A, et al. Expert consensus on the use of teprotumumab for the management of thyroid eye disease using a modified-Delphi approach. *J Neuroophthalmol*. 2022;42(3):334–9.
20. Wickwar S, McBain H, Edmunds MR, Ezra DG, Rose GE, Newman SP. Patients' expectations for the functional and psychosocial outcomes of orbital decompression surgery for thyroid eye disease: a qualitative study. *Psychol Health Med.* 2018;23(4):475–84.

Cite this article Varshney AS. Thyroid eye disease and orbital decompression: The precision art of reclaiming balance. *IP Int J Ocul Oncol Oculoplasty*. 2025;11(1):1-3.